Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen Idec and Amicus ally on Parkinson’s disease research

Biogen Idec and Amicus ally on Parkinson’s disease research

12th September 2013

Biogen Idec and Amicus Therapeutics have entered into a collaboration to discover, develop and commercialise novel small molecules for the treatment of Parkinson's disease.

The work will build upon preclinical studies by Amicus and independent research which suggests that increasing activity of the lysosomal enzyme glucocerobrosidase in the brain could help to correct alpha-synuclein pathology and other problems linked with the disease.

Over the course of several years, the companies will work together to discover a new class of molecules targeting this enzyme, with the resulting therapies to be developed and commercialised by Biogen Idec, which will also be responsible for funding the research.

Tim Harris, senior vice president of translational medicine at Biogen Idec, said: "Amicus has been a pioneer in the discovery of novel small molecules that increase GCase activity in the brain and we look forward to working together to discover potential treatments for Parkinson's disease."

This comes after Biogen Idec announced a new collaboration with Isis Pharmaceuticals focusing on the development of new neurological disease therapies earlier this week.ADNFCR-8000103-ID-801636604-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.